Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06520891
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-20
Brief Title:
The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
correlate the serum level of statin and SGLT2i when given as polytherapy with HPLC in ischemic heart failure patients and their laboratory tests cholesterol LDL HDL and TG
Detailed Description:
This is a prospective study that will carried out in Department of cardiology Faculty of Medicine Fayoum University during the period from 1 April 2024 to 1 Juley 2024 The study includes 90 Outpatients Clinic patients who met the inclusion criteria Patients will provide written informed consent before involving in this study
we will split the 90 patients into three groups
1 30 patients will take statin
2 30 patients will take SGLT2i
3 30 patients will take both of statin and SGLT2i
By collecting their blood samples and calculate the serum level of statin by using HPLC and calculate plasma level of SGLT2i by using HPLC as baseline first then after three months to predict the effect of each drug to another one we will follow their cholesterol triglyceride low density lipo-protein and high density lipo-protein and we will also inspect their adverse effects
we will split the 90 patients into three groups
1 30 patients will take statin
2 30 patients will take SGLT2i
3 30 patients will take both of statin and SGLT2i
By collecting their blood samples and calculate the serum level of statin by using HPLC and calculate plasma level of SGLT2i by using HPLC as baseline first then after three months to predict the effect of each drug to another one we will follow their cholesterol triglyceride low density lipo-protein and high density lipo-protein and we will also inspect their adverse effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None